n/a
Abstract Title:

French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double-blind, randomized, placebo-controlled trial.

Abstract Source:

J Eur Acad Dermatol Venereol. 2020 Aug 25. Epub 2020 Aug 25. PMID: 32841433

Abstract Author(s):

Paula Basso Lima, Joana Alexandria Ferreira Dias, Ana Cláudia Cavalcante Esposito, Luciane Donida Bartoli Miot, Hélio Amante Miot

Article Affiliation:

Paula Basso Lima

Abstract:

BACKGROUND: Melasma can be recalcitrant to treatment, and relapses are common. Pycnogenol has been reported to be effective in treating melasma.

OBJECTIVE: To compare the efficacy, safety, and tolerability of 75 mg pycnogenol taken orally twice a day versus a placebo, in association with the triple combination and broad-spectrum sunscreen for the treatment of facial melasma.

METHODS: A randomized, double-blind, parallel, placebo-controlled study was conducted on 44 women with facial melasma in a single centre from May 2019 through November 2019. Patients with melasma were randomly assigned to orally take 75 mg pycnogenol (PYC) or a placebo (PLAC) twice a day for 60 days. Both groups also received tinted sunscreen (SPF 50; PPD 17) for daytime use and a topical triple combination at bedtime. The primary outcome was a change from the baseline mMASI score. Secondary outcomes were improvements in the patients' quality of life (MELASQoL), colorimetric indices, and Global Aesthetic Improvement Scale (GAIS).

RESULTS: All participants completed the trial. The mean (SD) age of the participants was 39 (7) years, and 91% were phototypes III-IV. Both groups exhibited a reduction in mMASI scores, MELASQoL scores, and colour contrast (p<0.01). The mean (CI 95%) reductions of the mMASI scores were 49% (36-61%) for PYC and 34% (16-47%) for PLAC. The reductions in mMASI scores and colorimetric contrast were superior for the PYC group (p<0.05). The analysis of GAIS resulted in an improvement of 86% (CI 95% 68-96%) for the participants in the PYC group and 55% (CI 95% 32-73%) for those in the PLAC group. There were no adverse effects related to oral treatment.

CONCLUSION: Pycnogenol is well-tolerated and increases the effectiveness of broad-spectrum sunscreen and the triple combination in the treatment of facial melasma in women.

Study Type : Human Study

Print Options


Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2021 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.